There's Still Life in ValueClick

Recs

1

ValueClick (Nasdaq: VCLK) is living proof that the online advertising world doesn't start and stop with Google (Nasdaq: GOOG), Yahoo! (Nasdaq: YHOO), or Microsoft (Nasdaq: MSFT). Living and growing proof, in fact.

Fourth-quarter sales increased 14% over last year, and adjusted EBITDA (earnings before the inclusion of the depressing articles) came in flat. Some of the revenue boost came from two acquisitions in the comparison-shopping space over the past year, but even on an apples-to-apples comparison, ValueClick pulled out a 3% sales improvement.

Management credited the performance to the company's global scale and diversified service portfolio, and set the bar higher for next year with EBITDA margin targets that would describe the most efficient operations in three years. Payouts to advertising partners have remained consistent, and growth looks like a matter of driving more page views in front of the ad inventory.

The proposed Microsoft-Yahoo! merger is a non-issue to ValueClick's management, who say that the imaginary two-headed beast mainly deals in paid search, which is not ValueClick's main line of business. The real competition comes from smaller players like MIVA (Nasdaq: MIVA) and WPP Group (Nasdaq: WPPGY) subsidiary 24/7 Real Media.

This report also marked the end of a nine-month investigation by the FTC. ValueClick settled allegations of deceptive marketing practices with a $2.9 million payment, but without admitting to any wrongdoing. ValueClick and the FTC also agreed on the future "standards and practices that will govern" the company's lead generation business.

With an increased margin target, little fear of the proposed Microsoft-Yahoo! merger, and a clearer legal picture, ValueClick has increased its attractiveness as a takeover target in this acquisitive business climate.

Further Foolishness:

“Make Big Money With Options” Motley Fool CFO Ollen Douglass recently made over $100,000 buying options on 7 well known stocks. Now we’re committed to turning his small fortune into a massive one! And we want you to join us! Enter your email address to hear more:

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 578853, ~/Articles/ArticleHandler.aspx, 12/1/2009 11:18:10 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
The Public Health-Care Plan's Problem

Related Tickers

12/1/2009 10:30 AM
VCLK $9.59 Up +0.16 +1.72%
ValueClick, Inc. CAPS Rating: ***
MSFT $29.77 Up +0.36 +1.22%
Microsoft Corp CAPS Rating: ***
MIVA $0.22 Down +0.00 +0.00%
MIVA, INC. CAPS Rating: No stars
YHOO $14.98 Up +0.01 +0.07%
Yahoo!, Inc. CAPS Rating: **
GOOG $588.85 Up +5.85 +1.00%
Google, Inc. CAPS Rating: ***
WPPGY $47.98 Up +0.95 +2.02%
WPP Group plc (ADR… CAPS Rating: *****

Community: Investing Wiki

Term Of The Hour

PDUFA: The Prescription Drug User Fee Act (PDUFA) is a law enacted by Congress that gives powers to the FDA.

Want to learn more or edit this definition?
Click here to read more!